Literature DB >> 15592708

[Retroperitoneal lymph node dissection in testis cancer].

T Pottek1.   

Abstract

According to the rules of the European Interdisciplinary Consensus, retroperitoneal lymph node dissection (RPLND) will be indicated less frequently in patients with nonseminomatous testis cancer. In clinical stage I it will be done only exceptionally and in stage II A only in marker-negative patients. In all other stages RPLND will be recommended as residual tumor resection and additionally in "growing teratoma syndrome" and in rare situations as "desperation surgery." It will be difficult in future using the minor operations to enter the learning curve. Only advanced situations will have to be managed by urological surgeons. These operations will have to be performed predominantly in specialised centres.

Entities:  

Mesh:

Year:  2004        PMID: 15592708     DOI: 10.1007/s00120-004-0718-z

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  7 in total

1.  Evolution of retroperitoneal lymphadenectomy (RPLND) in the management of non-seminomatous testicular cancer (NSGCT).

Authors:  John P Donohue
Journal:  Urol Oncol       Date:  2003 Mar-Apr       Impact factor: 3.498

2.  The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients.

Authors:  F André; K Fizazi; S Culine; J Droz; P Taupin; C Lhommé; M Terrier-Lacombe; C Théodore
Journal:  Eur J Cancer       Date:  2000-07       Impact factor: 9.162

Review 3.  European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).

Authors:  H J Schmoll; R Souchon; S Krege; P Albers; J Beyer; C Kollmannsberger; S D Fossa; N E Skakkebaek; R de Wit; K Fizazi; J P Droz; G Pizzocaro; G Daugaard; P H M de Mulder; A Horwich; T Oliver; R Huddart; G Rosti; L Paz Ares; O Pont; J T Hartmann; N Aass; F Algaba; M Bamberg; I Bodrogi; C Bokemeyer; J Classen; S Clemm; S Culine; M de Wit; H G Derigs; K P Dieckmann; M Flasshove; X Garcia del Muro; A Gerl; J R Germa-Lluch; M Hartmann; A Heidenreich; W Hoeltl; J Joffe; W Jones; G Kaiser; O Klepp; S Kliesch; L Kisbenedek; K U Koehrmann; M Kuczyk; M P Laguna; O Leiva; V Loy; M D Mason; G M Mead; R P Mueller; N Nicolai; G O N Oosterhof; T Pottek; O Rick; H Schmidberger; F Sedlmayer; W Siegert; U Studer; S Tjulandin; H von der Maase; P Walz; S Weinknecht; L Weissbach; E Winter; C Wittekind
Journal:  Ann Oncol       Date:  2004-09       Impact factor: 32.976

4.  Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I.

Authors:  L Weissbach; E A Boedefeld
Journal:  J Urol       Date:  1987-07       Impact factor: 7.450

5.  Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.

Authors:  A G Aprikian; H W Herr; D F Bajorin; G J Bosl
Journal:  Cancer       Date:  1994-08-15       Impact factor: 6.860

6.  Complications of post-chemotherapy retroperitoneal lymph node dissection.

Authors:  J Baniel; R S Foster; R G Rowland; R Bihrle; J P Donohue
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

7.  Complications of primary retroperitoneal lymph node dissection.

Authors:  J Baniel; R S Foster; R G Rowland; R Bihrle; J P Donohue
Journal:  J Urol       Date:  1994-08       Impact factor: 7.450

  7 in total
  2 in total

Review 1.  [Aftercare in testicular cancer is worthwhile. Recurrences are curable].

Authors:  T S Pottek; K-P Dieckmann
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

Review 2.  Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature.

Authors:  Christian Guido Ruf; Simon Krampe; Cord Matthies; Petra Anheuser; Tim Nestler; Jörg Simon; Hendrik Isbarn; Klaus Peter Dieckmann
Journal:  World J Surg Oncol       Date:  2020-09-24       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.